Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $1.2 million.

  • Foghorn Therapeutics' Change in Accured Expenses fell 7671.56% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 17546.83%. This contributed to the annual value of -$564000.0 for FY2024, which is 6861.44% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported Change in Accured Expenses of $1.2 million as of Q3 2025, which was down 7671.56% from $2.0 million recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Change in Accured Expenses high stood at $5.0 million for Q3 2024, and its period low was -$2.8 million during Q1 2024.
  • For the 5-year period, Foghorn Therapeutics' Change in Accured Expenses averaged around $131684.2, with its median value being $690000.0 (2023).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 1524705.88% in 2021, then soared by 76414.47% in 2025.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Change in Accured Expenses stood at $2.4 million in 2021, then crashed by 62.75% to $894000.0 in 2022, then crashed by 62.86% to $332000.0 in 2023, then plummeted by 829.22% to -$2.4 million in 2024, then skyrocketed by 147.79% to $1.2 million in 2025.
  • Its Change in Accured Expenses was $1.2 million in Q3 2025, compared to $2.0 million in Q2 2025 and -$2.4 million in Q1 2025.